Serina Therapeutics, Inc. (SER)

NYSEAMERICAN: SER · Real-Time Price · USD
5.40
0.00 (0.00%)
At close: Jul 25, 2025, 4:00 PM
5.40
0.00 (0.00%)
After-hours: Jul 25, 2025, 4:10 PM EDT
Market Cap53.82M
Revenue (ttm)51,000
Net Income (ttm)-939,000
Shares Out 9.97M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,791
Open5.40
Previous Close5.40
Day's Range5.40 - 5.54
52-Week Range3.81 - 11.57
Betan/a
AnalystsStrong Buy
Price Target13.00 (+140.74%)
Earnings DateAug 8, 2025

About SER

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In additio... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 29, 2018
Employees 13
Stock Exchange NYSEAMERICAN
Ticker Symbol SER
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SER stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 140.74% from the latest price.

Price Target
$13.0
(140.74% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advance...

15 days ago - GlobeNewsWire

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has establi...

24 days ago - GlobeNewsWire

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimi...

4 weeks ago - GlobeNewsWire

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

5 weeks ago - GlobeNewsWire

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimizati...

5 weeks ago - GlobeNewsWire

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Featuring Serina Therapeutics' CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise...

6 weeks ago - GlobeNewsWire

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics –

2 months ago - GlobeNewsWire

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced...

2 months ago - GlobeNewsWire

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimizatio...

2 months ago - GlobeNewsWire

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optim...

3 months ago - GlobeNewsWire

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optim...

3 months ago - GlobeNewsWire

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug op...

3 months ago - GlobeNewsWire

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optim...

3 months ago - GlobeNewsWire

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimizat...

4 months ago - GlobeNewsWire

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug deliv...

4 months ago - GlobeNewsWire

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimi...

5 months ago - GlobeNewsWire

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $...

6 months ago - GlobeNewsWire

Serina Therapeutics Announces Sale of UniverXome Subsidiary

- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinica...

6 months ago - GlobeNewsWire

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delive...

6 months ago - GlobeNewsWire

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.  (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug deliv...

7 months ago - GlobeNewsWire

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delive...

8 months ago - GlobeNewsWire

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with str...

8 months ago - GlobeNewsWire

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Pa...

9 months ago - GlobeNewsWire

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery techno...

11 months ago - GlobeNewsWire

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics  (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery techno...

1 year ago - GlobeNewsWire